{"id":"W4249938708","doi":"10.1158/1538-7445.sabcs18-ct158","title":"Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Trials","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ovarian cancer; Nivolumab; Oncology; Placebo; Double blind; Chemotherapy; Internal medicine; Front line; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001174218,0.001928937,0.002253705,0.0007629425,0.0004778718,0.001092622,0.001170388,0.002156581,0.01219096],"category_scores_gemma":[0.0007851825,0.0007292277,0.001301157,0.0004521626,0.001166824,0.0008612658,0.0003797828,0.003218119,0.002171234],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007216986,"about_ca_system_score_gemma":0.001513143,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00132118,"about_ca_topic_score_gemma":0.004041679,"domain_scores_codex":[0.9996035,0.0001796959,0.00001867299,0.0000895298,0.00002957838,0.00007903094],"domain_scores_gemma":[0.9995652,0.00005904305,0.00007852023,0.00002929652,0.0000266929,0.0002411907],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.937706,0.02159755,0.0004450472,0.0009368173,0.0008324549,0.00006225926,0.00004460221,0.0004125485,0.008912644,0.0002713621,0.00252878,0.02624992],"study_design_scores_gemma":[0.9327444,0.064209,0.0009405074,0.00003185346,0.0001947025,0.00002737239,0.00001070498,0.0002966379,0.0004428942,0.0001106752,0.0009784851,0.00001278194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9636995,0.007173363,0.001389944,0.001231945,0.001015687,0.01395124,0.003443042,0.0006621473,0.007433176],"genre_scores_gemma":[0.9571694,0.003455127,0.003757291,0.003636794,0.0005766834,0.01365197,0.003036812,0.00008474002,0.01463116],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01219096,"threshold_uncertainty_score":0.04078287,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1940413944317502,"score_gpt":0.4964910619994237,"score_spread":0.3024496675676735,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}